Biophore

Executive Summary

Biophore is a private Indian contract development and manufacturing organization (CDMO) focused on small-molecule APIs, intermediates, and niche pharmaceutical products. Established in 2020 and based in Hyderabad, the company leverages FDA- and EU-approved facilities, a broad drug master file (DMF) portfolio, and expertise in complex chemistry to serve global generics and specialty drug markets. Its therapeutic areas include oncology, contrast agents, peptides, injectable APIs, and orphan drugs. Biophore accelerates product development and market entry for its clients, positioning itself as a reliable partner in the fast-growing CDMO space. The company’s recent establishment and focus on high-value, complex molecules suggest potential for rapid growth, though it faces competition from established CDMOs. With no disclosed funding or valuation, Biophore’s financial profile is opaque, but its operational capabilities in regulated markets indicate a credible offering.

Upcoming Catalysts (preview)

• Q2 2026FDA Approval for New Injectable API70% success
• 2026Strategic Partnership with Global Generic Firm60% success
• Q4 2026Expansion of Peptide Manufacturing Capacity80% success